Jasper Therapeutics, Inc.
JSPR Nasdaq
SEC CIK 1788028
Follow Jasper Therapeutics
Weekly email: filings, results
Revenue, last quarter
$8M
Net income
−$144.5M
−671% vs same quarter last year
EPS, diluted
−$10.19
+68.2% vs same quarter last year
Operating cash flow
−$5.5M
+67.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$75.8 |
| FY24 | −$71.3M |
| FY23 | −$64.5M |
| FY22 | −$37.7M |
| FY21 | −$30.6M |
| FY20 | −$31.7M |
| FY19 | - |